EVOXAC Drug Patent Profile
✉ Email this page to a colleague
When do Evoxac patents expire, and what generic alternatives are available?
Evoxac is a drug marketed by Cosette and is included in one NDA.
The generic ingredient in EVOXAC is cevimeline hydrochloride. There are four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cevimeline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Evoxac
A generic version of EVOXAC was approved as cevimeline hydrochloride by HIKMA on July 8th, 2013.
Summary for EVOXAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 96 |
Clinical Trials: | 3 |
Patent Applications: | 82 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EVOXAC |
What excipients (inactive ingredients) are in EVOXAC? | EVOXAC excipients list |
DailyMed Link: | EVOXAC at DailyMed |
Recent Clinical Trials for EVOXAC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Roxane Laboratories | Early Phase 1 |
American Academy of Otolaryngology-Head and Neck Surgery Foundation | Phase 4 |
Duke University | Phase 4 |
Pharmacology for EVOXAC
Drug Class | Cholinergic Receptor Agonist |
Mechanism of Action | Cholinergic Muscarinic Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for EVOXAC
Paragraph IV (Patent) Challenges for EVOXAC
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
EVOXAC | Capsules | cevimeline hydrochloride | 30 mg | 020989 | 1 | 2009-02-27 |
US Patents and Regulatory Information for EVOXAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cosette | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EVOXAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cosette | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
Cosette | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
Cosette | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EVOXAC
See the table below for patents covering EVOXAC around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 0205247 | DERIVATIVES OF QUINUCLIDINE | ⤷ Try a Trial |
Israel | 106218 | Pharmaceutical compositions containing a spiro (1,3-oxathiolane-5,3') quinuclidine derivative for curing sjoegren syndrome disease | ⤷ Try a Trial |
Japan | 2852608 | ⤷ Try a Trial | |
Canada | 2099970 | COMPOSE POUR LE TRAITEMENT DU SYNDROME DE SJOEGREN (COMPOSITION FOR CURING SJOEGREN SYNDROME DISEASE) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |